Alzheimer's disease（AD） - Medical Tourism & Treatment Guide in China

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by amyloid-beta plaque deposition, neurofibrillary tangles composed of hyperphosphorylated tau protein, and consequent synaptic loss and neuronal death—primarily affecting the hippocampus and cerebral cortex. Clinically, it manifests as insidious-onset episodic memory impairment, followed by deficits in executive function, language, visuospatial processing, and behavioral regulation. Diagnosis integrates clinical evaluation, neuropsychological testing (e.g., MMSE, MoCA), structural MRI to assess medial temporal lobe atrophy, FDG-PET for hypometabolism patterns, and increasingly, CSF biomarkers (Aβ42, p-tau, total tau) or plasma phosphorylated tau-217 assays. While no disease-modifying therapy is yet curative, acetylcholinesterase inhibitors (donepezil, rivastigmine) and NMDA receptor antagonists (memantine) provide symptomatic stabilization; recent anti-amyloid monoclonal antibodies (e.g., lecanemab, donanemab) are under rigorous clinical evaluation in China’s Phase III trials with local regulatory oversight.

China offers distinct advantages for Alzheimer’s care: leading neurology centers—including Peking Union Medical College Hospital and Huashan Hospital—maintain specialized cognitive disorder clinics staffed by physicians trained in both Western and integrative approaches, with deep expertise in early differential diagnosis and multimodal management. Advanced imaging infrastructure (3T MRI, digital PET-CT) and AI-powered cognitive assessment platforms support precision phenotyping. Real-world evidence from over 12,000 patients treated across tier-1 hospitals demonstrates consistent functional stabilization rates comparable to international benchmarks. Crucially, comprehensive diagnostic workups and 12-month pharmacologic/nonpharmacologic interventions cost approximately 40–60% less than equivalent care in the US or Western Europe—without compromising clinical rigor or safety standards.

As a dedicated medical tourism agency, we facilitate seamless access for international patients: vetting accredited neurology centers, coordinating appointments with dementia specialists, clarifying all-inclusive pricing upfront (including consultations, diagnostics, medications, and caregiver support), and providing end-to-end assistance—from visa documentation and medical translation to post-discharge follow-up coordination. Our role ensures continuity, transparency, and personalized navigation through China’s high-quality, cost-efficient Alzheimer’s care ecosystem.